UBS Maintains Buy on Amgen, Raises Price Target to $400

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

UBS analyst Michael Yee maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $390 to $400.

Comments

No comments yet. Be the first!